Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00345878 |
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women. This study will evaluate the immunogenicity and safety of the HPV-16/18 L1 VLP AS04 vaccine.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Condition | Intervention | Phase |
---|---|---|
Human Papillomavirus (HPV) Infection Associated Cervical Neoplasia |
Biological: HPV-16/18 L1 VLP AS04 |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase IIIb, Double-Blind, Randomized, Controlled Study to Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine Administered Intramuscularly ( 0, 1, 6 Month Schedule) in Healthy Women From Malaysia. |
Estimated Enrollment: | 300 |
Study Start Date: | September 2006 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
The protocol was primarily amended for the following reasons:
Ages Eligible for Study: | 18 Years to 35 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Malaysia | |
GSK Investigational Site | |
Kuala Lumpur, Malaysia, 50603 | |
GSK Investigational Site | |
Kerajaan Persekutuan Putrajaya, Malaysia, 62250 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 105926 |
Study First Received: | June 28, 2006 |
Last Updated: | October 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00345878 |
Health Authority: | Malaysia: Ministry of Health |
HPV HPV-16/18 L1 VLP AS04 AS04 |
Cervical cancer Cervical neoplasia Double-blind |
Healthy |
Infection |